Christopherg Twitty News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Posted April 15th, 2021 for OncoSec Medical
April 15, 2021 8:30am EDT
PENNINGTON, N.J. and SAN DIEGO, April 15, 2021 / /  OncoSec Medical Incorporated (NASDAQ:ONCS) (the Company or OncoSec ), a biotechnology company focused on cytokine-based intratumoral immunotherapies, today announced that it will be presenting encore interim data from its KEYNOTE-695 registration-enabled Phase 2b clinical trial evaluating TAVO™ (tavokinogene telseplasmid), a DNA plasmid-based interleukin-12 (IL-12), in combination with KEYTRUDA
® (pembrolizumab) in rigorously defined anti-PD1 checkpoint resistant metastatic melanoma patients at the 10
th World Congress of Melanoma. This is an encore presentation of data presented at The Society for Immunotherapy of Cancer s (SITC) 2020 Annual Meeting. Presenters will also discuss the therapeutic potential of OncoSec s DNA medicines platform to elicit robust anti-tumor immunity via intratumoral gene electrotransfer of TAV ....

Christopherg Twitty , Paolo Ascierto , Paoloa Ascierto , Oncosec Medical Incorporated , National Tumor Institute Fondazioneg Pascale , Society For Immunotherapy Of Cancer , Company Or Oncosec , Drug Administration , Food Drug Administration , World Congress , Innovative Therapy , National Tumor Institute Fondazione , Fast Track Designation , Orphan Drug , சமூகம் க்கு நோயெதிர்ப்பு சிகிச்சை ஆஃப் புற்றுநோய் , உலகம் காங்கிரஸ் , புதுமையானது சிகிச்சை , வேகமாக டிராக் பதவி , ஆர்ஃபந் மருந்து ,